AstraZeneca’s chief medical officer announces resignation amid wave of departures

pharmafile | January 14, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

AstraZeneca’s Sean Bohen has announced he will step down from his role as chief medical officer at the Anglo-Swedish drugmaker amid speculation that he would be leaving the firm.

Bohen’s departure has come amid a series of high profile resignations as both Mark Mallon and Bahija Jallal jumped ship. Analyst Tim Anderson, who noted on Friday that Bohen was likely to leave, suggested that “the optics of having respected leaders leave a company are never good.”

The recent wave of departures coincides with a sweeping organisational shake up which will see a major restructuring of the firm.

Bohen will remain in his current role to oversee the company’s transition towards its new organisational structure and until a new chief medical office has been confirmed.

The restructuring will see research and development split into two parts: one of which will be concerned with oncology while the other will focus on biopharmaceuticals.

While the disgraced cancer doctor Jose Baselga will lead the oncology arm, AstraZeneca veteran Mene Pangalos will lead the biopharmaceutical section of the firm.

Related Content

No items found

Latest content